Interferon alfa-2a

Overview

Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.

Indication

For the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection.

Associated Conditions

Chronic Hepatitis B Infection
Chronic Hepatitis C Virus (HCV) Infection
Chronic Myelogenous Leukemia (CML)
Cutaneous T-Cell Lymphoma (CTCL)
Hairy Cell Leukemia (HCL)
Kaposi's Sarcoma
Multiple Myeloma (MM)
Non-Hodgkin's Lymphoma (NHL)
Thrombocytosis

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.	2018/12/11	NCT03771677	Not Applicable	Recruiting	Sun Yat-sen University
Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis	2017/07/06	NCT03209219	Phase 3	Completed	Peking Union Medical College Hospital
Bevacizumab in Metastatic Renal Cancer	2015/12/10	NCT02627144	N/A	Completed	Hoffmann-La Roche
Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)	2015/04/30	NCT02430194	Phase 2	Completed	Eiger BioPharmaceuticals
Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection	2015/01/19	NCT02340962	Phase 2	Completed	TaiGen Biotechnology Co., Ltd.
Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines	2014/06/10	NCT02159482	Phase 2	Terminated	Duke University
A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic Clear Cell Renal Cell Carcinoma (RCC).	2008/11/24	NCT00796757	Phase 2	Completed	Hoffmann-La Roche
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer	2008/07/21	NCT00719264	Phase 2	Completed	Novartis Pharmaceuticals
Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma	2008/02/20	NCT00619268	Phase 2	Completed	Centre Leon Berard
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.	2007/08/24	NCT00520403	Phase 2	Completed	Hoffmann-La Roche

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
ROFERON-A SOLN-LIQ IM SC 9MILLION I.U./ML	Hoffmann-La Roche Limited	02217058	Solution - Subcutaneous , Intramuscular	9 M / ML	4/25/1997
ROFERON-A SOLUTION INJ. 9MILLION I.U./0.9ML	Hoffmann-La Roche Limited	02019914	Solution - Intramuscular , Subcutaneous	9000000 UNIT / .9 ML	12/31/1993
ROFERON A STERILE PWS 18M UNIT/VIAL	Hoffmann-La Roche Limited	01912003	Powder For Solution - Subcutaneous , Intramuscular	18000000 UNIT / VIAL	12/31/1991
ROFERON A STERILE PWS 9M UNIT/VIAL	Hoffmann-La Roche Limited	01911996	Powder For Solution - Subcutaneous , Intramuscular	9000000 UNIT / VIAL	12/31/1991
ROFERON-A SOLUTION INJ 36000000UNIT/ML	Hoffmann-La Roche Limited	00891002	Solution - Intramuscular , Subcutaneous	36000000 UNIT / ML	12/31/1992
ROFERON-A SOLN-LIQ IM SC 4.5MILLION I.U/ML	Hoffmann-La Roche Limited	02217023	Liquid - Intramuscular , Subcutaneous	4.5 M / ML	4/25/1997
ROFERON-A SOLUTION 3 MILLION I.U./ML	Hoffmann-La Roche Limited	02217015	Solution - Subcutaneous , Intramuscular	3 M / ML	2/25/1997
ROFERON-A SOLUTION 18 MILLION I.U./3ML	Hoffmann-La Roche Limited	02217066	Solution - Subcutaneous , Intramuscular	18 M / 3 ML	1/15/1997
ROFERON-A SOLUTION 6 MILLION I.U./ML	Hoffmann-La Roche Limited	02217031	Solution - Subcutaneous , Intramuscular	6 M / ML	2/24/1997
ROFERON A SOLN INJ 6 MILLION	Hoffmann-La Roche Limited	00812498	Liquid - Intramuscular , Subcutaneous	6000000 UNIT / ML	12/31/1989

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
ROFERON - A 9 MILLONES DE UNIDADES INTERNACIONALES (UI) SOLUCION INYECTABLE EN JERINGA PRECARGADA	Roche Farma S.A.	62994	SOLUCIÓN INYECTABLE EN JERINGA PRECARGADA	Diagnóstico Hospitalario	Not Commercialized
ROFERON - A 3 MILLONES DE UNIDADES INTERNACIONALES (UI) SOLUCION INYECTABLE EN JERINGA PRECARGADA	Roche Farma S.A.	62999	SOLUCIÓN INYECTABLE EN JERINGA PRECARGADA	Diagnóstico Hospitalario	Not Commercialized

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access